Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 28

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 28
---
 will solicit and pay the cost of soliciting proxies? |

| A: | Enfusion will pay for the proxy solicitation costs related to the Special Meeting. Enfusion has engaged                                                                                                                                              
 Innisfree to assist in the solicitation of proxies for the Special Meeting. Enfusion estimates that it will pay Innisfree a fee of approximately $20,000, plus reasonable                                                                            
 out-of-pocket expenses. Enfusion will also reimburse banks, brokerage firms, custodians, trustees, nominees and fiduciaries who hold shares for the benefit of another                                                                               
 party for their expenses incurred in sending proxies and proxy materials to beneficial owners of Enfusion Common Stock. Enfusion’s directors, officers and employees also may solicit proxies in person by telephone or over the Internet. They will 
 not be paid any additional amounts for soliciting proxies.                                                                                                                                                                                           |

| Q: | How can I find more information about Clearwater and Enfusion? |

| A: | You can find more information about Clearwater and Enfusion from various sources described in the section 
 titled “Where You Can Find More Information.”                                                             |

| Q: | Who can answer any questions I may have about the Special Meeting or the proxy materials? |

| A: | If you have any questions about the Special Meeting, the Transactions, the proposals or this Proxy                                                                                                                                                      
 Statement/Prospectus, would like additional copies of the Proxy Statement/Prospectus, need to obtain proxy cards or other information related to this proxy solicitation or need help submitting a proxy or voting your shares of Enfusion Common Stock 
 or Enfusion Class B Common Stock, you should contact Enfusion or Innisfree:                                                                                                                                                                             |

| Enfusion, Inc.                                                 
 125 South Clark Street, Suite 750                              
 Chicago, IL 60603 (312) 253-9800 Attention: Investor Relations |     | Innisfree M&A Incorporated                                                       
 501 Madison Avenue, 20th Floor                                                   
 New York City, NY 10022 Banks and                                                
 Brokerage Firms Call: (212) 750-5833 Stockholders Call Toll Free: (877) 750-0637 |

12

SUMMARY

The following summary highlights selected information described in more detail elsewhere in this Proxy Statement/Prospectus and the documents incorporated by reference into this Proxy Statement/Prospectus and may not contain all the information that may be important to you. To understand the Transactions and the matters being voted on by Enfusion Stockholders at the Special Meeting more fully, and